CN103212117A - Cobalt-chromium alloy arterial stent system with full biodegrade medical coating - Google Patents
Cobalt-chromium alloy arterial stent system with full biodegrade medical coating Download PDFInfo
- Publication number
- CN103212117A CN103212117A CN 201310102113 CN201310102113A CN103212117A CN 103212117 A CN103212117 A CN 103212117A CN 201310102113 CN201310102113 CN 201310102113 CN 201310102113 A CN201310102113 A CN 201310102113A CN 103212117 A CN103212117 A CN 103212117A
- Authority
- CN
- China
- Prior art keywords
- support
- coating
- cochrome
- medication coat
- complete biodegradable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000576 coating method Methods 0.000 title abstract description 140
- 239000011248 coating agent Substances 0.000 title abstract description 134
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical class [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 title abstract 4
- 239000003814 drug Substances 0.000 claims description 80
- 229940079593 drug Drugs 0.000 claims description 63
- 230000006698 induction Effects 0.000 claims description 26
- 210000003205 muscle Anatomy 0.000 claims description 23
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 11
- 239000004626 polylactic acid Substances 0.000 claims description 11
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 9
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 9
- 229960002930 sirolimus Drugs 0.000 claims description 9
- 229930012538 Paclitaxel Natural products 0.000 claims description 7
- 229960001592 paclitaxel Drugs 0.000 claims description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 16
- 230000008569 process Effects 0.000 abstract description 9
- 201000000057 Coronary Stenosis Diseases 0.000 abstract 1
- 206010056489 Coronary artery restenosis Diseases 0.000 abstract 1
- 206010011089 Coronary artery stenosis Diseases 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 description 27
- 239000002184 metal Substances 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 238000000746 purification Methods 0.000 description 20
- 239000007921 spray Substances 0.000 description 17
- 239000007789 gas Substances 0.000 description 14
- 210000004204 blood vessel Anatomy 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 229910052756 noble gas Inorganic materials 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 238000005520 cutting process Methods 0.000 description 7
- 238000010147 laser engraving Methods 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 238000002161 passivation Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 238000005498 polishing Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 239000000428 dust Substances 0.000 description 5
- 210000003038 endothelium Anatomy 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 230000008676 import Effects 0.000 description 5
- 238000010327 methods by industry Methods 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 229910052743 krypton Inorganic materials 0.000 description 4
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 229910052704 radon Inorganic materials 0.000 description 4
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 229910000619 316 stainless steel Inorganic materials 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000009513 drug distribution Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052754 neon Inorganic materials 0.000 description 2
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 230000002966 stenotic effect Effects 0.000 description 2
- 210000004026 tunica intima Anatomy 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000008398 formation water Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000052 poly(p-xylylene) Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012890 simulated body fluid Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005491 wire drawing Methods 0.000 description 1
Images
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention provides a cobalt-chromium alloy arterial stent system with a full biodegrade medical coating. The system comprises a transport system and a cobalt-chromium alloy arterial stent which has a full biodegrade medical coating and is sleeved on the transport system. The transport system comprises a push rod, a sacculus and a jacket respectively fixedly connected to both ends of the push rod, and a handle with a Luer joint. A cone-shaped hardened guide wire is arranged at the sacculus end of the push rod. The cobalt-chromium alloy arterial stent with the full biodegrade medical coating is sleeved on the sacculus. The system can avoid damage of the coating to the maximum extent, improve the retaining force between the bracket and the transport system greatly, prevent the probability that the bracket is out of load in the transport process, and reduce the clinical use risk, so that the problems of coronary artery stenosis and restenosis are effectively solved.
Description
The application is that application number is 201010034532.9, name is called: " having cochrome arterial bracket, mounting system of complete biodegradable medication coat and preparation method thereof ", the applying date are: the dividing an application of the application for a patent for invention on January 21st, 2010.
Technical field
The present invention relates to a kind of cochrome arterial bracket system with complete biodegradable medication coat.
Background technology
Since first naked metal rack Palmaz-Schatz of the U.S. in 1985 inserts human body, cause arteria coronaria vascular restenosis rate very high with balloon expandable merely, the operation of support interventional therapy can successfully solve this difficult problem, become the main means of clinical treatment, the technology of interventional therapy has experienced the epoch of naked metal rack to the bracket for eluting medicament development again afterwards.Nowadays bracket for eluting medicament went on the market 5 years.The rapamycin bracket for eluting medicament that is rack platform with medical 316 rustless steels has become one of main treatment product of coronary heart disease both at home and abroad.At present domestic in arterypuncture coronary angioplasty PCI interventional therapy, rustless steel rapamycin bracket for eluting medicament is used in a large number, to the treatment of ischemic coronary heart disease and safety by a large amount of clinical evidences checkings.But in operation, when 316 stainless steel stents are carried by blood vessel is interior, there are a lot of weak points compliance, pathological changes trafficability characteristic, radial support power aspect, and because after traditional non-degraded medication coat FirebirdTM implants, because of rack surface coating non-degradable, directly cause blood vessel endotheliumization bad or endothelialization is slow with the blood vessel endothelium reaction that is inflamed, thus make subacute and incidence rate advanced thrombus higher, thrombosis becomes the fatal principal element of coronary heart disease interventional therapy.The degradable eluting coatings is degraded gradually behind implant into body, greatly avoided because of coating and blood vessel endothelium directly the thrombosis that causes of effect take place, therefore a kind of degradable coating with better compliance, pathological changes trafficability characteristic, radial support power will become one of new development direction of drug stent.
In the interventional therapy operation, support is held diameter by pressure and is met under the situation of requirement of blood vessel, be transported to the pathological change of thrombus place by induction systems such as sacculus bodies by blood vessel in the very long body, because technical problem, support and induction system generally by pressure hold form that a system sells and, with convenient clinical use, but because the coating of conventional medicament rack surface takes the one pole coating technology to be shaped more at present, adhesive force is relatively poor, this makes to combine insecure between coating and backbone metal platform and hold in pressure and causes coating damage in the process easily, passing through stenotic lesion, make breakdown of coating when tortuous pathological changes or calcify lesion easily, thereby cause the drug distribution inequality, directly have influence on the effectiveness and the safety of drug stent; In addition, the back adopts the tangential technology of holding of pressing because the mounting system medium-height trestle is set on the sacculus body of induction system, the tangential pressure held the damage that inevitably causes because of surperficial tangent direction friction in the scheme coating, and because tangential limitation of pressing the technology of holding, make that the indwelling power between support and the induction system is less, thereby make support in that not occur taking off the probability of carrying in vivo in the moving process with the sacculus body under the expansion state as yet very big, easily cause the failure of operation.
Therefore, each drug stent of the whole world provides the commercial city to be devoted to research and develop test in the rack platform of optimizing, newtype drug, drug regimen, safer coating technology and the fields such as mounting system farthest avoiding the damage of coating and have better indwelling power.
Summary of the invention
The technical problem that the present invention solves provides a kind of radial grading and presses the cochrome arterial bracket system with complete biodegradable medication coat that technology makes of holding, can farthest avoid the damage of coating, and increase substantially the indwelling power between support and the induction system, avoid occurring support and in transportation, take off the probability of carrying, reduce clinical application risk, effectively solved coronary stricture and restenosis problem.
The present invention is achieved through the following technical solutions:
A kind of cochrome arterial bracket system with complete biodegradable medication coat comprises induction system and is set in the cochrome arterial bracket with complete biodegradable medication coat on the induction system;
Described induction system comprise push rod, respectively be fixedly connected on the push rod two ends sacculus body and sheath, be provided with the hands handle of female Luer; This push rod sacculus body end is provided with taper and adds stiff guide wire; Described cochrome arterial bracket with complete biodegradable medication coat is set on the sacculus body;
Described cochrome arterial bracket with complete biodegradable medication coat comprises the complete biodegradable medication coat that applies on the thin wall hollow ferrule holder that cut into by cochrome L605 tubing engraving and the support, this support comprises the connecting rod that is circumferentially with 6-9 sinusoidal wave unitary support bar and axially is connected two adjacent support bars, and the unitary Wave crest and wave trough of this sine wave is by two straight-bars and circular arc linkage section composition; The sinusoidal wave unitary trough of described adjacent supports bar, crest are respectively relatively, described connecting rod is arranged at intervals on the two relative troughs of two adjacent sinusoidal configuration, and be provided with a connecting rod on each trough at most, this connecting rod comprises continuous " S " type linkage section and straight-bar linkage section, be somebody's turn to do the outside of the described trough relatively of " S " type linkage section one end connection, the inboard of another trough of connection of this straight-bar linkage section.
Preferably, described complete biodegradable medication coat is by 0.2～0.5 part by weight: the medicine and the medical degradable polylactic acid of 0.3～1.0 part ratio proportioning are formed, and described medicine is rapamycin or paclitaxel.
Preferably, described circular arc linkage section is approximate " Ω " type bent angle structure.
Preferably, the muscle wide region of the circular arc linkage section of described support bar is 0.07112～0.0762mm, and straight-bar muscle wide region is 0.0762～0.0889mm, and the muscle wide region of connecting rod is 0.06604～0.07112mm.
A kind of above-mentioned preparation method with cochrome arterial bracket of complete biodegradable medication coat, it may further comprise the steps:
⑴ be prepared into the thin wall hollow ferrule holder with cochrome L605 tubing electrochemical polishing treatment after the laser engraving cutting;
⑵ carry out pretreatment to described support:
Cleaning surfaces is handled: clean rack surface with purified water;
⑶ the preparation of nitrogen or noble gas:
1. filter purification: nitrogen or noble gas carry out the secondary filter purification;
2. in the nitrogen or noble gas input surface passivation blood processor with purification, the expulsion pressure of adjusting surperficial Passivation Treatment device is 0.1～0.15bar, and gas flow is 1.0～1.5 milliliters/second, sprays nitrogen or noble gas uniformly to rack surface;
⑷ dispose coating solution: 0.2～0.5 part of rapamycin of medical degradable polylactic acid adding or the paclitaxel of 0.3～1.0 part of parts by weight are made into a kind of coating solution, and the coating coating machine of packing into;
⑸ carry out the gradation coating on pretreated metal rack: start the coating coating machine, coating solution is atomized, nitrogen or the noble gas of opening purification simultaneously continue the spray processing to rack surface, described metal rack is carried out 6～9 coating coatings, and when each coating coating finishes, with purification nitrogen after filtering or noble gas coating was sprayed 10～30 minutes, make air-flow cover the bracket coating surface, reach 90～150 μ g/cm up to drug loading
2
Preferably, described cochrome arterial bracket with complete biodegradable medication coat is pressed by radial grading and is held on the sacculus body of induction system, wherein said radial grading is pressed and held is that the outer surface of coated stent is repeatedly pressed along the radially equipressure of support cross section and held, wherein, press grip pressure power scope 50 newton/cm
2～80 newton/cm
2, temperature is controlled between 18～50 ℃, described support is carried out 8～11 classifications pressure hold, the each pressure held 5 seconds～12 seconds, closely be nested on the sacculus body up to support, make indwelling power between support and sacculus body greater than 1.54 newton, guaranteeing has good indwelling power between support and the sacculus.
The present invention has the following advantages:
(1) cochrome open loop structure rack platform design
(a) adopt the L605 cochrome as the rack platform material, carry out rack forming by L605 cochrome tubing being carried out processing such as laser engraving cutting and electrochemical polish, the mechanical strength of L605 cochrome is stainless 1.8 times of traditional coronary artery bracket material-316L, its biocompatibility excellence, so this support simultaneously adopts L605 cochrome material to improve the overall biology and the mechanical performance of support.
Because of the L605 cochrome has stronger mechanical strength, therefore in the supporting structure design, take thin-walled design and the design of thin bar, when guaranteeing powerful radial support power, increased substantially the overall compliance of support, make support simultaneously behind implant into body, thereby the arteria coronaria endotheliocyte can cover rack surface rapidly shortens arteria coronaria endothelium repair time to reduce the incidence rate of thrombosis, and safety is improved.
(b) support bar is taked 0.0028 inch～0.0035 inch (the non-wide lath type design of 0.07112～0.0889mm) width range, the lath type design has reduced the overall metal coverage rate of support, scope is between 11%～15%, local inflammation reaction and damage behind the human body have been reduced to insert, thereby make restenosis rate, clinical indices such as subacute stent thrombosis incidence rate and advanced thrombus incidence rate are improved, the straightway width of support bar is bigger, scope is at 0.0030 inch～0.0035 inch (0.0762～0.0889mm), to improve radial support power and X ray development, and it is less at support bar corner width, scope is at the inch of 0.0028 inch～0.0030(0.07112～0.0762mm), with metal stresses and the deformation that reduces corner, guarantee that it reduces the occurrence probability that face coat strips off from now on as the drug stent platform time.The support connecting rod is taked the long sinusoidal lath type design of " S " type of fitting a straight line (width is littler than the support bar width), width range is at 0.0026 inch～0.0028 inch (0.06604～0.07112mm), wherein the rectilinearity linkage section increases submissive connection overall length, reduced submissive section axial stress, and compression takes place or stretches in the sinusoidal wave unit of " S " type when support carries out bending and expansion, therefore the axial compliance of support is greatly improved, the adherent property of axial blood vessel and the vascular compliance of support have been improved simultaneously, the normal physiological of malleable blood vessel is not out of shape to make support, has reduced the damage to blood vessel.
(c) support bar circular arc linkage section is that corner adopts " Ω " type bent angle structure, this structure radius of curvature is little, the support bar width of this part is starkly lower than support bar straightway part simultaneously, therefore obviously reduced the warpage pressure of support bar, the rebound degree of this part is descended, when carrying out support and carrying sacculus to press to hold assembling, support is more closely combined with carrying sacculus, be not easy to take place resilience, thereby obviously improve the support retentivity, in clinical manipulation, lowered the support that causes because of retentivity the is not enough incidence rate that comes off.Make support bar have bigger warpage space simultaneously, (0.85mm-1.08mm), obviously improved the trafficability characteristic of this support is that clinical manipulation is more reliably convenient to have the littler external diameter that passes through after support is pressed and held.After the support expansion, " Ω " type bent angle structure is fully opened, and makes the linear type support bar of its both sides become 40 degree～50 degree angles, increases the radial support power of this support from mechanical structure.
(d) steric configuration of support is taked " crest-trough ", open cell and the submissive linkage section mode of helical arrangement at interval.The arrangement mode of supporting section " crest-trough " makes support to arrange between support unit under the prerequisite that keeps long submissive linkage section more tight, thereby it is more even that the rack space Metal Distribution is covered, be difficult for taking place prolapsing or the excessive phenomenon of local metal density after inserting human body because of the uneven speckle that causes of Metal Distribution, success rate of operation and restenosis incidence rate at a specified future date all are improved, in addition, even metal covers and makes this support satisfy the uniformity requirement of drug stent carrier platform to drug distribution.Open cell circumferentially is Unit 6～9, this design has increased the support side shoot and has passed through potentiality when improving the support compliance, when carry out side shoot by and side shoot when expansion, open unit can fully be expanded, and makes clinical easier collateral blood vessels is handled.The mode of submissive linkage section interval helical arrangement makes the axial compliance of support more even when further improving the space Metal Distribution, has reduced the generation of " fish scale " and " perk " phenomenon.The Cycle Length of " S " type sine curve part is consistent with the outer electrical path length of " Ω " type bent angle structure of supporting section in submissive linkage section, has avoided in other supports because of the circumferentially adherent bad generation of the excessive blood vessel that causes of bendability syndeton Cycle Length.
(2) biodegradable coating material
The carrier mechanism that adopts the medical grade polylactic acid to upload, fix and discharge as medicine, polylactic acid was degraded to water and carbon dioxide through 120 days left and right sides time in vivo, discharge fully through metabolism, retain in vivo without any non-biological material finishing under the prerequisite of medicine controlled releasing, reduce adverse events odds such as advanced thrombus thereby increased substantially the endothelium speed of repairing.
(3) coating solution optimization of C
Optimize the component ratio of coating solution, described coating of degradable medicaments is by 0.2～0.5 part by weight: the rapamycin and the medical grade polylactic acid of 0.3～1.0 part ratio proportioning are formed.Make coating solution uniformity more in applying film forming process, and has a more rational organic solvent evaporation rate, make the rack surface coating not be prone to into the generation of bad phenomenon such as web, wire drawing, uneven thickness, organic solvent noresidue simultaneously, thus avoided support that the phenomenon of drug distribution inequality takes place behind implant into body.
(4) multistage coating paint-on technique: in the conventional coatings coating procedure, adopt the method for single application more or soak film forming method, the coating toughness that these methods make is lower, tensile strength is less, when after support is inserted human body, expanding at rack surface, particularly the support corner concentrates just easy generation coating to chap, and when serious coating can take place also and strip off, thereby this will cause drug release inequality, the local serious clinical adverse consequences that forms blood flow eddy current initiation thrombosis.Coating process carries out step by step, rack surface is carried out not waiting thick coating, increase substantially the toughness and the adhesion-tight degree of coating, be difficult for stripping off at support expansion, moving process floating coat, thereby the stability that has improved bracket coating has avoided support to strip off the occurrence probability of the bad clinical events such as acute and subacute stent thrombosis that cause because of coating composition in the back that implants.
(5) metal rack platform surface noble gas treatment process: in the conventional coatings coating process, in order to improve the adhesion-tight degree of coating and rack surface, certainly will pass through the way precoating layer Parylene coating of vacuum vapor deposition on the backbone metal surface, but this coating is nonbiodegradable, permanent being retained in the human body of meeting, lost the meaning of degraded coating, therefore, the coating of degrading fully keeps the technology of outstanding firmness extremely important simultaneously.We take controlled noble gas coating processing is carried out on the backbone metal surface, reduce the surface tension of metal rack, make the coating atomizing particle more even firm in the backbone metal surface, the toughness and the adhesion-tight degree of raising coating
(6) radial grading is pressed and held technology: the 316L medical stainless steel more commonly used because of the L605 cochrome has bigger elastic modelling quantity, hold effect for reaching better pressure, therefore holding in pressure needs in the process that support is carried out 9～11 classifications and presses and hold, the each pressure keeps certain temperature and time when holding, temperature range is 18 ℃～50 ℃, time range is 5 seconds～12 seconds, indwelling power between support and the induction system increased substantially, thereby avoided support to move in vivo and do not take off the probability of carrying under the expansion state as yet.In addition, hold in the scheme coating that inevitably causes for traditional tangential pressure and hold damage in the process in pressure because of surperficial tangent direction friction, taked novel radially pressure to hold scheme, by radially evenly exerting pressure of 12 directions support pressed and to hold, farthest avoided the damage of coating.
Description of drawings
Fig. 1 is the flat deployable structure sketch map that the present invention has the cochrome arterial bracket of complete biodegradable medication coat;
Fig. 2 is the structural representation that the present invention has the cochrome arterial bracket system of complete biodegradable medication coat.
The specific embodiment
As shown in Figure 1, a kind of cochrome arterial bracket with complete biodegradable medication coat, it comprises the complete biodegradable medication coat that applies on the thin wall hollow ferrule holder that cut into by cochrome L605 tubing engraving and the support, this support comprises the connecting rod 2 that is circumferentially with 6 unitary support bars 1 of sine wave and axially is connected two adjacent support bars, the unitary crest 3 of this sine wave, trough 4 are formed by two straight-bars 5 and circular arc linkage section 6, and the muscle of described circular arc linkage section 6 is wide all wide smaller or equal to the muscle of straight-bar 5; The sinusoidal wave unitary crest 3 of described adjacent supports bar 1, trough 4 are respectively relatively, described connecting rod 2 is arranged at intervals on the two relative troughs 4 of two adjacent sinusoidal configuration, and be provided with a connecting rod 2 on each trough 4 at most, this connecting rod 2 is connected to form by horizontally set " S " type linkage section 7 and straight-bar linkage section 8, be somebody's turn to do the outside of the described trough 41 relatively of " S " type linkage section 8 one ends connection, the inboard of another trough 42 of the connection of this straight-bar linkage section 8.
Described support is taked non-wide lath type design, and wherein, the muscle of the circular arc linkage section of support bar is wide to be 0.07112mm, and the straight-bar muscle is wide to be 0.0762mm, and the muscle of connecting rod is wide to be 0.06604mm.
Described preparation method with cochrome arterial bracket of complete biodegradable medication coat, it may further comprise the steps:
⑴ be prepared into the thin wall hollow ferrule holder with cochrome L605 tubing electrochemical polishing treatment after the laser engraving cutting;
⑵ carry out pretreatment to described support:
Carrying out cleaning surfaces handles: rack surface is cleaned with purified water, remove the little bits micronic dust in the support process engineering;
⑶ carry out the cascade filtration purification to argon, imports then in the surface passivation blood processor, and the adjustment expulsion pressure is 0.1bar, and gas flow is 1.0 milliliters/second, sprays uniform argon to rack surface;
⑷ dispose coating solution: 0.25 part of paclitaxel of medical degradable polylactic acid adding of 0.4 part of parts by weight is made into a kind of coating solution, and the coating coating machine of packing into;
⑸ carry out the gradation layered coating on pretreated metal rack: start the coating coating machine, coating solution is atomized, the argon of opening purification simultaneously sprays processing to rack surface, and described metal rack is carried out coating spraying 6 times, reaches 90 μ g/cm up to drug loading
2And when each coating finishes, coating was continued spray 10～30 minutes, make air-flow cover the bracket coating surface, organic solvent in the coating is volatilized fast and make the coating fast setting, until finishing bracket coating with the purification argon after filtering.
As shown in Figure 2, a kind of cochrome arterial bracket system with complete biodegradable medication coat, comprise induction system and be set on the induction system and press the described cochrome arterial bracket of holding 10 with complete biodegradable medication coat by radial grading, described induction system comprise push rod 11, respectively be fixedly connected on push rod 11 two ends sacculus body 12 and plastic H UB sheath 13, be provided with the handle 14 of female Luer; This push rod middle part is provided with seal wire mouth changeover portion 15, and sacculus body end is provided with taper and adds stiff guide wire 16; Described cochrome arterial bracket 10 with complete biodegradable medication coat is set on the sacculus body 12.
Described cochrome arterial bracket with complete biodegradable medication coat is pressed by radial grading and is held on the sacculus body of induction system, wherein said radial grading is pressed and held is that the outer surface of coated stent is repeatedly pressed along the radially equipressure of support cross section and held, wherein, described support is carried out 9 classifications pressure to be held, the each pressure held 5 seconds～12 seconds, pressed grip pressure power 50 newton/cm
2Temperature is controlled at 50 ℃, closely be nested on the sacculus body up to support, making the indwelling power between support and sacculus body is 1.54 newton, indwelling power between support and the induction system is increased substantially, thereby avoided support to move in vivo and do not taken off the probability of carrying under the expansion state as yet, farthest avoided the damage of coating.
This system is by the induction system percutaneous puncture, add in taper under the guiding of stiff guide wire 16 and enter coronary artery, because the indwelling power between support 10 and the induction system increases substantially, thereby assurance support 10 does not take off in the moving process and between the sacculus body 12 in very long body and carries, arrive the vascular lesion position smoothly, induction system is implemented and is withdrawed from after pressurization discharges support 10, and support 10 struts stenotic lesion, recover blood flow, reach therapeutic purposes.Support 10 is implanted there is control the back by default release profiles release medicine, medicine enters the pharmacological action that the performance of local vascular inner membrance suppresses the tunica intima cell proliferation, the release medication coat of concomitant drugs is finished 90% above degradation process about 120 days simultaneously, excretes through internal metabolism formation water and carbon dioxide.
The difference of present embodiment and embodiment 1 is:
The muscle wide region of the circular arc linkage section of described support bar is 0.0762mm, and straight-bar muscle wide region is 0.0889mm, and the muscle wide region of connecting rod is 0.07112mm.
Described preparation method with cochrome arterial bracket of complete biodegradable medication coat, it may further comprise the steps:
⑴ be prepared into the thin wall hollow ferrule holder with cochrome L605 tubing electrochemical polishing treatment after the laser engraving cutting;
⑵ carry out pretreatment to described support:
Carrying out cleaning surfaces handles: rack surface is cleaned with purified water, remove the little bits micronic dust in the support process engineering;
⑶ carry out the cascade filtration purification to radon gas, imports then in the surface passivation blood processor, and the adjustment expulsion pressure is 0.15bar, and gas flow is 1.5 milliliters/second, sprays uniform radon gas to rack surface;
⑷ dispose coating solution: 0.5 part of paclitaxel of medical degradable polylactic acid adding of 0.6 part of parts by weight is made into a kind of coating solution, and the coating coating machine of packing into;
⑸ carry out the gradation layered coating on pretreated metal rack: start the coating coating machine, coating solution is atomized, the radon gas of opening purification simultaneously sprays processing to rack surface, and described metal rack is carried out coating spraying 7 times, reaches 90 μ g/cm up to drug loading
2And when each coating finishes, coating was continued spray 20 minutes, make air-flow cover the bracket coating surface, organic solvent in the coating is volatilized fast and make the coating fast setting, until finishing bracket coating with the purification radon gas after filtering.
Described support 10 is carried out 8 classifications pressure hold, the each pressure held 5 seconds～12 seconds, pressed grip pressure power 60 newton/cm
2Temperature is controlled at 20 ℃, closely be nested on the sacculus body up to support, the indwelling power that makes 12 of support 10 and sacculus bodies is 4.9 newton, indwelling power between support and the induction system is increased substantially, thereby avoided support to move in vivo and do not taken off the probability of carrying under the expansion state as yet, farthest avoided the damage of coating.Like this, make cochrome arterial bracket system with complete biodegradable medication coat.
The difference of present embodiment and embodiment 1 is:
The muscle wide region of the circular arc linkage section of described support bar is 0.0762mm, and straight-bar muscle wide region is 0.0762mm, and the muscle wide region of connecting rod is 0.07mm.
Described preparation method with cochrome arterial bracket of complete biodegradable medication coat, it may further comprise the steps:
⑴ be prepared into the thin wall hollow ferrule holder with cochrome L605 tubing electrochemical polishing treatment after the laser engraving cutting;
⑵ carry out pretreatment to described support:
Carrying out cleaning surfaces handles: rack surface is cleaned with purified water, remove the little bits micronic dust in the support process engineering;
⑶ carry out the cascade filtration purification to nitrogen, imports then in the surface passivation blood processor, and the adjustment expulsion pressure is 0.14bar, and gas flow is 1.3 milliliters/second, sprays uniform nitrogen to rack surface;
⑷ dispose coating solution: 0.5 part of paclitaxel of medical degradable polylactic acid adding of 0.8 part of parts by weight is made into a kind of coating solution, and the coating coating machine of packing into;
⑸ carry out the gradation layered coating on pretreated metal rack: start the coating coating machine, coating solution is atomized, the nitrogen of opening purification simultaneously sprays processing to rack surface, and described metal rack is carried out coating spraying 8 times, reaches 120 μ g/cm up to drug loading
2And when each coating finishes, coating was continued spray 30 minutes, make air-flow cover the bracket coating surface, organic solvent in the coating is volatilized fast and make the coating fast setting, until finishing bracket coating with the purification nitrogen after filtering.
Described support 10 is carried out 10 classifications pressure hold, the each pressure held 12 seconds, pressed grip pressure power 70 newton/cm
2Temperature is controlled at 40 ℃, closely be nested on the sacculus body up to support, the indwelling power that makes 12 of support 10 and sacculus bodies is 2.9 newton, indwelling power between support and the induction system is increased substantially, thereby avoided support to move in vivo and do not taken off the probability of carrying under the expansion state as yet, farthest avoided the damage of coating.Like this, make cochrome arterial bracket system with complete biodegradable medication coat.
Embodiment 4
The difference of present embodiment and embodiment 1 is:
The muscle wide region of the circular arc linkage section of described support bar is 0.072mm, and straight-bar muscle wide region is 0.08mm, and the muscle wide region of connecting rod is 0.067mm.Described preparation method with cochrome arterial bracket of complete biodegradable medication coat, it may further comprise the steps:
⑴ be prepared into the thin wall hollow ferrule holder with cochrome L605 tubing electrochemical polishing treatment after the laser engraving cutting;
⑵ carry out pretreatment to described support:
Carrying out cleaning surfaces handles: rack surface is cleaned with purified water, remove the little bits micronic dust in the support process engineering;
⑶ carry out the cascade filtration purification to krypton gas, imports then in the surface passivation blood processor, and the adjustment expulsion pressure is 0.14bar, and gas flow is 1.5 milliliters/second, sprays uniform krypton gas to rack surface;
⑷ dispose coating solution: 0.4 part of rapamycin of medical degradable polylactic acid adding of 0.8 part of parts by weight is made into a kind of coating solution, and the coating coating machine of packing into;
⑸ carry out the gradation layered coating on pretreated metal rack: start the coating coating machine, coating solution is atomized, the krypton gas of opening purification simultaneously sprays processing to rack surface, and described metal rack is carried out coating spraying 9 times, reaches 130 μ g/cm up to drug loading
2And when each coating finishes, coating was continued spray 10 minutes, make air-flow cover the bracket coating surface, organic solvent in the coating is volatilized fast and make the coating fast setting, until finishing bracket coating with the purification krypton gas after filtering.
Described support 10 is carried out 11 classifications pressure hold, the each pressure held 5 seconds, pressed grip pressure power 80 newton/cm
2Temperature is controlled at 18 ℃, closely be nested on the sacculus body up to support, the indwelling power that makes 12 of support 10 and sacculus bodies is 3.9 newton, indwelling power between support and the induction system is increased substantially, thereby avoided support to move in vivo and do not taken off the probability of carrying under the expansion state as yet, farthest avoided the damage of coating.Like this, make cochrome arterial bracket system with complete biodegradable medication coat.
Embodiment 5
The difference of present embodiment and embodiment 1 is:
The muscle wide region of the circular arc linkage section of described support bar is 0.07112mm, and straight-bar muscle wide region is 0.078mm, and the muscle wide region of connecting rod is 0.07112mm.
Described preparation method with cochrome arterial bracket of complete biodegradable medication coat, it may further comprise the steps:
⑴ be prepared into the thin wall hollow ferrule holder with cochrome L605 tubing electrochemical polishing treatment after the laser engraving cutting;
⑵ carry out pretreatment to described support:
Carrying out cleaning surfaces handles: rack surface is cleaned with purified water, remove the little bits micronic dust in the support process engineering;
⑶ carry out the cascade filtration purification to neon, imports then in the surface passivation blood processor, and the adjustment expulsion pressure is 0.1bar, and gas flow is 1.0 milliliters/second, sprays uniform neon to rack surface;
⑷ dispose coating solution: 0.2 part of rapamycin of medical degradable polylactic acid adding of 0.3 part of parts by weight is made into a kind of coating solution, and the coating coating machine of packing into;
⑸ carry out the gradation layered coating on pretreated metal rack: start the coating coating machine, coating solution is atomized, the nitrogen of opening purification simultaneously sprays processing to rack surface, and described metal rack is carried out coating spraying 9 times, reaches 110 μ g/cm up to drug loading
2And when each coating finishes, coating is continued spray, make air-flow cover the bracket coating surface, organic solvent in the coating is volatilized fast and make the coating fast setting, until finishing bracket coating with the purification nitrogen after filtering.
Described support 10 is carried out 10 classifications pressure hold, press grip pressure power 75 newton/cm
2Temperature is controlled at 40 ℃, closely be nested on the sacculus body up to support, the indwelling power that makes 12 of support 10 and sacculus bodies is 4 newton, indwelling power between support and the induction system is increased substantially, thereby avoided support to move in vivo and do not taken off the probability of carrying under the expansion state as yet, farthest avoided the damage of coating.Like this, make cochrome arterial bracket system with complete biodegradable medication coat.
Embodiment 6
Present embodiment provides a kind of study on the efficiency method with cochrome arterial bracket of complete biodegradable medication coat:
The study on the efficiency that the present invention promptly contains the cochrome arterial bracket with complete biodegradable medication coat of paclitaxel or rapamycin medicine is to carry out excessively pulling on the coronary artery model of pig.The main terminal point of research: 4 weeks were observed terminal point, by scanning electron microscopic observation tunica intima, endothelium coverage condition; Vascular morphology learn to be measured neointimal hyperplasia index (on the support between inner film thickness, support inner film thickness, new intima area).
Embodiment 7
The cochrome arterial bracket release in vitro assay method that present embodiment provides the present invention to have the complete biodegradable medication coat:
18 cochrome arterial brackets (3 of each testing time points) with complete biodegradable medication coat are placed brown test tube with ground stopper, add the 20ml simulated body fluid simultaneously (with phosphate-buffered salt a slice, be dissolved in the water for injection of 1L, add 0.5% sodium azide solution, cryopreservation gets final product at the bovine serum albumin that faces with preceding adding 4%), put into the constant temperature culture agitator at different time points, rotating speed 100 times/minute, amplitude 2cm, test temperature is 37 ± 2 ℃.At 6 hours, 24 hours, 3 days, 7 days, 14 days, carried out release test in 28 days.
Take out drug stent release time in accordance with regulations, with 20 minutes eluting of acetonitrile supersonic vibration, take out support, with acetonitrile flushing support and with flushing liquor to the 25ml volumetric flask to scale, filtrate is measured medicament contg with HPLC, calculates the ratio that the medicine that discharges accounts for original drug loading.
High-efficient liquid phase chromatogram condition:
Chromatographic column is C18 post (4.6mm * 15mm, 5 μ m)
Mobile phase: acetonitrile: methanol: water (30: 50: 25)
Column temperature: 55 ℃ are detected wavelength: 230nm
Sample size: 20 μ l flow velocity: 1.0ml/min.
Claims (5)
1. have the cochrome arterial bracket system of complete biodegradable medication coat, it is characterized in that, comprise induction system and be set in cochrome arterial bracket on the induction system with complete biodegradable medication coat;
Described induction system comprise push rod, respectively be fixedly connected on the push rod two ends sacculus body and sheath, be provided with the hands handle of female Luer; This push rod sacculus body end is provided with taper and adds stiff guide wire; Described cochrome arterial bracket with complete biodegradable medication coat is set on the sacculus body;
Described cochrome arterial bracket with complete biodegradable medication coat comprises the complete biodegradable medication coat that applies on the thin wall hollow ferrule holder that cut into by cochrome L605 tubing engraving and the support, this support comprises the connecting rod that is circumferentially with 6-9 sinusoidal wave unitary support bar and axially is connected two adjacent support bars, and the unitary Wave crest and wave trough of this sine wave is by two straight-bars and circular arc linkage section composition; The sinusoidal wave unitary trough of described adjacent supports bar, crest are respectively relatively, described connecting rod is arranged at intervals on the two relative troughs of two adjacent sinusoidal configuration, and be provided with a connecting rod on each trough at most, this connecting rod comprises continuous " S " type linkage section and straight-bar linkage section, be somebody's turn to do the outside of the described trough relatively of " S " type linkage section one end connection, the inboard of another trough of connection of this straight-bar linkage section.
2. the cochrome arterial bracket with complete biodegradable medication coat according to claim 1, it is characterized in that, described complete biodegradable medication coat is by 0.2～0.5 part by weight: the medicine and the medical degradable polylactic acid of 0.3～1.0 part ratio proportioning are formed, and described medicine is rapamycin or paclitaxel.
3. the cochrome arterial bracket with complete biodegradable medication coat according to claim 1 is characterized in that, described circular arc linkage section is approximate " Ω " type bent angle structure.
4. the cochrome arterial bracket with complete biodegradable medication coat according to claim 1, it is characterized in that, the muscle wide region of the circular arc linkage section of described support bar is 0.07112～0.0762mm, straight-bar muscle wide region is 0.0762～0.0889mm, and the muscle wide region of connecting rod is 0.06604～0.07112mm.
5. the cochrome arterial bracket system with complete biodegradable medication coat according to claim 1, it is characterized in that, described cochrome arterial bracket with complete biodegradable medication coat is pressed by radial grading and is held on the sacculus body of induction system, wherein said radial grading is pressed and held is that the outer surface of coated stent is repeatedly pressed along the radially equipressure of support cross section and held, wherein, press grip pressure power scope 50 newton/cm
2～80 newton/cm
2, temperature is controlled between 18～50 ℃, described support is carried out 8～11 classifications press and to hold, and each the pressure held 5 seconds～12 seconds, closely was nested on the sacculus body up to support, made indwelling power between support and sacculus body greater than 1.54 newton.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310102113.8A CN103212117B (en) | 2010-01-21 | 2010-01-21 | Cobalt-chromium alloy arterial stent system with full biodegrade medical coating |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310102113.8A CN103212117B (en) | 2010-01-21 | 2010-01-21 | Cobalt-chromium alloy arterial stent system with full biodegrade medical coating |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010034532.9A Division CN101745153B (en) | 2010-01-21 | 2010-01-21 | Cobalt-chromium alloy artery stent with full-biodegradation medicine coating, stent system and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103212117A true CN103212117A (en) | 2013-07-24 |
| CN103212117B CN103212117B (en) | 2014-11-26 |
Family
ID=48810489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310102113.8A Active CN103212117B (en) | 2010-01-21 | 2010-01-21 | Cobalt-chromium alloy arterial stent system with full biodegrade medical coating |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103212117B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105902331A (en) * | 2016-04-08 | 2016-08-31 | 南京永明医疗器械有限公司 | Intravascular stent and preparation method thereof |
| CN108186175A (en) * | 2018-02-02 | 2018-06-22 | 青岛市中心医院 | A kind of novel and multifunctional Internal Medicine-Cardiovascular Dept. coronary artery bracket |
| CN111529152A (en) * | 2020-05-15 | 2020-08-14 | 上海君联医疗设备有限公司 | a vascular stent |
| CN117959594A (en) * | 2024-01-31 | 2024-05-03 | 深圳深安医疗科技有限公司 | Implantable tumor suppression device, manufacturing method thereof and suppression equipment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2880013Y (en) * | 2005-12-12 | 2007-03-21 | 北京乐普医疗器械有限公司 | Delivery Devices for Bifurcated Vascular Stents |
| CN101314059A (en) * | 2007-06-01 | 2008-12-03 | 张煦 | Artery medicine elution bracket |
-
2010
- 2010-01-21 CN CN201310102113.8A patent/CN103212117B/en active Active
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105902331A (en) * | 2016-04-08 | 2016-08-31 | 南京永明医疗器械有限公司 | Intravascular stent and preparation method thereof |
| CN108186175A (en) * | 2018-02-02 | 2018-06-22 | 青岛市中心医院 | A kind of novel and multifunctional Internal Medicine-Cardiovascular Dept. coronary artery bracket |
| CN111529152A (en) * | 2020-05-15 | 2020-08-14 | 上海君联医疗设备有限公司 | a vascular stent |
| CN117959594A (en) * | 2024-01-31 | 2024-05-03 | 深圳深安医疗科技有限公司 | Implantable tumor suppression device, manufacturing method thereof and suppression equipment |
| CN117959594B (en) * | 2024-01-31 | 2024-10-11 | 深圳深安医疗科技有限公司 | Implantable tumor suppression device, manufacturing method thereof and suppression equipment |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103212117B (en) | 2014-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101745153B (en) | Cobalt-chromium alloy artery stent with full-biodegradation medicine coating, stent system and preparation method thereof | |
| CN101862233B (en) | Drug-delivery endovascular stent and method for treating restenosis | |
| CN102309368B (en) | Body lumen drug-carrying bracket and preparation method thereof | |
| CN105726174B (en) | A kind of intravascular stent, preparation method and application | |
| CN101313873B (en) | Biology polypeptide medicament blood vessel bracket and preparation method thereof | |
| CN109985280A (en) | Medicinal balloon and preparation method thereof | |
| CN103212117B (en) | Cobalt-chromium alloy arterial stent system with full biodegrade medical coating | |
| CN101600463B (en) | Drug-delivery endovascular stent and method of use | |
| Richter et al. | Relationship between blood flow, thrombus, and neointima in stents | |
| US20020065551A1 (en) | Method for immobilizing poly(HEMA) on stents | |
| CN101601616B (en) | Intracranial sirolimus medicament-release blood vessel stent and preparation method thereof | |
| CN201055442Y (en) | Novel blood vessel support | |
| CN101485902A (en) | Biodegradable rapamycin-probucol composite medicine coating metal stent | |
| CN106618821B (en) | A kind of intravascular stent for preventing reangiostenosis and preparation method thereof | |
| CN103990186B (en) | A kind of have support of control restenosis medicaments coating and preparation method thereof | |
| CN101601617B (en) | Intracranial paclitaxel medicament release stent and preparation method thereof | |
| CN101195047A (en) | Antithrombotic and restenosis blood vessel bracket and method for preparing the same | |
| CN102309781A (en) | Coronary stent containing recombinant human cellular repressor of E1 A-stimulated genes (hCREG) glycoprotein and preparation method for coronary stent | |
| CN202146455U (en) | Cardiovascular composite medicine bracket | |
| CN102711676A (en) | Stent | |
| KR101770827B1 (en) | Stent for selectively capturing epc and process for producing the same | |
| CN114051417A (en) | Drug dissolution type stent | |
| CN104707185A (en) | Ginkgolide B composite medicine eluting stent | |
| JP2007515974A (en) | Method for preparing drug-eluting medical device and medical device obtained by the method | |
| CN100500113C (en) | Stainless steel cardiovascular bracket with pharmaceutical coating on surface and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Cobalt-chromium alloy arterial stent system with full biodegrade medical coating Effective date of registration: 20160310 Granted publication date: 20141126 Pledgee: Beijing technology intellectual property financing Company limited by guarantee Pledgor: Medfavour (Beijing) Medical Equipment Co., Ltd. Registration number: 2016990000194 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20170711 Granted publication date: 20141126 |
|
| PP01 | Preservation of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190509 Granted publication date: 20141126 Pledgee: Beijing technology intellectual property financing Company limited by guarantee Pledgor: Medfavour (Beijing) Medical Equipment Co., Ltd. Registration number: 2016990000194 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20200711 Granted publication date: 20141126 |
|
| PD01 | Discharge of preservation of patent |